(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2014 (28.08.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/130657 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 38/00* (2006.01)
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2014/017364

(22) International Filing Date:
20 February 2014 (20.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/767,071 20 February 2013 (20.02.2013) US
61/888,255 8 October 2013 (08.10.2013) US

(71) Applicants: **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). **UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION** [US/US]; 200 Gardner Steel Conference Center, Thackeray and O'Hara Streets, Pittsburgh, PA 15260 (US).

(72) Inventor; and
(71) Applicant : **BROGDON, Jennifer** [US/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US).

(72) Inventors; and
(71) Applicants *(for US only)*: **JOHNSON, Laura Alexandra** [CA/US]; 111 Armat Avenue, Ardmore, PA 19003 (US). **JUNE, Carl H.** [US/US]; 409 Baird Road, Merion Station, PA 19066 (US).

(72) Inventor; and
(71) Applicant : **LOEW, Andreas** [DE/US]; 50 Bow Street, Apt. #9, Somerville, MA 02143 (US).

(72) Inventors; and
(71) Applicants *(for US only)*: **MAUS, Marcela** [—/US]; 705 Haviland Drive, Bryn Mawr, PA 19010 (US). **SCHOLLER, John** [US/US]; 410 Gilpin Road, Narberth, PA 19072 (US). **OKADA, Hideho** [JP/US]; 3008 Beechwood Blvd, Pittsburgh, PA 15206 (US).

(74) Agent: **LAWRENCE, Laurie Butler**; Lando & Anastasi LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR




FIG. 1A




FIG. 1B

(57) Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti- EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

WO 2014/130657 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*